New mRNA boosters show promise in phase 2 trial

NCT ID NCT05960097

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tested new COVID-19 mRNA booster vaccines in 692 healthy adults who had already received their primary vaccine series. The goal was to see how well the boosters boosted immunity and whether they were safe. Participants received either an experimental vaccine or a control vaccine, and researchers monitored side effects and antibody levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID - 19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Sacramento, California, 95864, United States

  • GSK Investigational Site

    Hollywood, Florida, 33024, United States

  • GSK Investigational Site

    Peoria, Illinois, 61614-4896, United States

  • GSK Investigational Site

    Bruce, Australian Capital Territory, 2617, Australia

  • GSK Investigational Site

    Blacktown, New South Wales, 2148, Australia

  • GSK Investigational Site

    Botany, New South Wales, 2019, Australia

  • GSK Investigational Site

    Brookvale, New South Wales, 2100, Australia

  • GSK Investigational Site

    Coffs Harbour, New South Wales, 2450, Australia

  • GSK Investigational Site

    Darlinghurst, New South Wales, 2010, Australia

  • GSK Investigational Site

    Kanwal, New South Wales, 2259, Australia

  • GSK Investigational Site

    Maroubra, New South Wales, 2035, Australia

  • GSK Investigational Site

    Merewether, New South Wales, 2291, Australia

  • GSK Investigational Site

    Blacktown, Queensland, 4006, Australia

  • GSK Investigational Site

    Sherwood, Queensland, 4068, Australia

  • GSK Investigational Site

    Tarragindi, Queensland, 4075, Australia

  • GSK Investigational Site

    Adelaide, South Australia, 5000, Australia

  • GSK Investigational Site

    Camberwell, Victoria, 3124, Australia

Conditions

Explore the condition pages connected to this study.